Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

Breast |  Colon |  Leukemia |  Lung |  Lymphoma |  Myelomas |  Pancreatic |  Prostate |

Breast

Colon

Leukemia

Lung

Lymphoma

Myelomas

Pancreatic

  • Capecitabine +/- Ruxolitinib for Metastatic Pancreatic Cancer
    A randomized, double-blind, phase 3 study of the JAK1/2 inhibitor, Ruxolitinib or Placebo in combination with Capecitabine in subjects with advanced or metastatic adenocarcinoma of the pancreas who have failed or are intolerant to first-line chemotherapy

Prostate